These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 31603993)
1. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699 [TBL] [Abstract][Full Text] [Related]
3. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746 [TBL] [Abstract][Full Text] [Related]
4. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Bian C; Yao K; Li L; Yi T; Zhao X Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168 [TBL] [Abstract][Full Text] [Related]
5. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669 [TBL] [Abstract][Full Text] [Related]
6. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer. Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221 [TBL] [Abstract][Full Text] [Related]
8. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551 [TBL] [Abstract][Full Text] [Related]
9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer. Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994 [TBL] [Abstract][Full Text] [Related]
11. Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer. Tyagi K; Roy A; Mandal S Mol Biol Rep; 2024 Sep; 51(1):983. PubMed ID: 39276277 [TBL] [Abstract][Full Text] [Related]
12. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501 [TBL] [Abstract][Full Text] [Related]
13. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan. Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969 [TBL] [Abstract][Full Text] [Related]
14. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Ren B; Guo W; Chen X J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779 [TBL] [Abstract][Full Text] [Related]
15. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392 [TBL] [Abstract][Full Text] [Related]
16. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Xu X; Deng F; Lv M; Chen X Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927 [TBL] [Abstract][Full Text] [Related]
17. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955 [TBL] [Abstract][Full Text] [Related]
18. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. Lee YJ; Kim HS; Rim JH; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT BMC Cancer; 2020 Mar; 20(1):185. PubMed ID: 32131779 [TBL] [Abstract][Full Text] [Related]
19. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes. Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119 [TBL] [Abstract][Full Text] [Related]
20. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Takaya H; Nakai H; Sakai K; Nishio K; Murakami K; Mandai M; Matsumura N Gynecol Oncol; 2020 Feb; 156(2):415-422. PubMed ID: 31785864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]